GlassScriptPhysician profile
Bethany A Baird
NPI 1306481031
$6,268.60
in general payments reported to CMS, 2019-2025
41 companies · $3,210 in 2025
The $3,210 reported for 2025 was more than what 97% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $157 · 2022: $156 · 2023: $885 · 2024: $1,861 · 2025: $3,210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,625 · Education: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,625.37 |
| Education | $330.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,972.85 | 2022-2025 | Enhertu, Datroway, Injectafer |
| Novartis Pharmaceuticals Corporation | $435.12 | 2023-2025 | |
| Janssen Biotech, INC. | $397.31 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Astrazeneca Pharmaceuticals LP | $334.59 | 2023-2025 | Imfinzi, Enhertu, Calquence |
| Pfizer INC. | $250.70 | 2023-2025 | |
| Sobi, INC | $221.70 | 2024-2025 | |
| Celgene Corporation | $213.70 | 2023-2025 | Reblozyl, Pomalyst |
| Lilly USA, LLC | $213.42 | 2023 | Verzenio, Retevmo, Jaypirca |
| Foundation Medicine, INC. | $203.19 | 2021-2023 | |
| Exelixis INC. | $191.38 | 2024-2025 | Cabometyx |
| Abbvie INC. | $156.56 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $144.23 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Genentech USA, INC. | $137.21 | 2023-2025 | Alecensa, Tecentriq, Polivy |
| Incyte Corporation | $122.93 | 2025 | Jakafi |
| Beone Medicines USA, INC. | $117.86 | 2025 | Brukinsa, Tevimbra |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $95.13 | 2024-2025 | Vyloy, Xospata |
| Eisai INC. | $85.74 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.70 | 2025 | |
| Geron Corporation | $67.41 | 2024-2025 | Rytelo |
| Genmab U.S., INC. | $65.69 | 2024-2025 | Epkinly, Tivdak |
| Viiv Healthcare Company | $62.17 | 2023-2024 | Apretude |
| Array Biopharma INC | $60.59 | 2025 | Lorbrena, Mektovi, Braftovi |
| Regeneron Healthcare Solutions, INC. | $57.90 | 2024-2025 | Libtayo |
| Gilead Sciences, INC. | $55.52 | 2025 | Trodelvy |
| Genzyme Corporation | $53.19 | 2025 | |
| Amgen INC. | $48.70 | 2023 | Vectibix, Nplate, Xgeva |
| Coherus Oncology, INC. | $46.37 | 2025 | Loqtorzi |
| E.R. Squibb & Sons, L.L.C. | $42.78 | 2024-2025 | Reblozyl, Eliquis |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2024-2025 | Fruzaqla, Vpriv |
| Sumitomo Pharma America, INC. | $37.80 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $37.03 | 2023-2025 | Orserdu |
| Beigene USA, INC. | $33.33 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $31.56 | 2025 | Xpovio |
| Avyxa Pharma, LLC | $24.45 | 2025 | |
| Glaxosmithkline, LLC. | $23.50 | 2025 | Ojjaara, Blenrep |
| Seagen INC. | $21.86 | 2023 | Adcetris |
| Dendreon Pharmaceuticals LLC | $20.87 | 2024 | Provenge |
| Spectrum Pharmaceuticals INC. | $19.85 | 2023 | Rolvedon |
| Emd Serono, INC. | $19.79 | 2025 | |
| Novocure INC. | $18.40 | 2024 | Optune Lua (Novottf-200t) |
| Inogen, INC. | $18.29 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Baird listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.